OBSOLETE: Renal cell carcinoma associated with neuroblastoma

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

No FDA or trial events recorded yet for OBSOLETE: Renal cell carcinoma associated with neuroblastoma.

Financial Assistance

2 programs

FINANCIAL LANDSCAPE SUMMARY

2

Total programs

2

Open now

Patient Assistance Programs2

TECENTRIQ

Genentech, Inc.

OpenContact for detailsApply ↗

OPDIVO

E.R. Squibb & Sons, L.L.C.

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

2 FDA-approved

OPDIVO

(NIVOLUMAB)standard

E.R. Squibb & Sons, L.L.C.

Programmed Death Receptor-1 Blocking Antibody [EPC]

12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytoki...

FDA label ↗

LENVIMA

(lenvatinib)Orphan drugstandard

Eisai Inc.

Kinase Inhibitor [EPC]

12.1 Mechanism of Action Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors V...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for OBSOLETE: Renal cell carcinoma associated with neuroblastoma.
Search all trials →
Search clinical trials for OBSOLETE: Renal cell carcinoma associated with neuroblastoma

Recent News & Research

No recent news articles indexed yet for OBSOLETE: Renal cell carcinoma associated with neuroblastoma.
Search PubMed for OBSOLETE: Renal cell carcinoma associated with neuroblastoma

Browse all OBSOLETE: Renal cell carcinoma associated with neuroblastoma news →

Specialist Network

No specialists currently listed for OBSOLETE: Renal cell carcinoma associated with neuroblastoma.

View all OBSOLETE: Renal cell carcinoma associated with neuroblastoma specialists →

Quick Actions